Question 1

What is the difference between Trulicity and Victoza?

Accepted Answer

Trulicity and Victoza both treat type 2 diabetes with GLP-1 receptor agonists, but the cadence and engineering diverge. Trulicity is dulaglutide, a GLP-1 analogue fused to a modified IgG4 antibody fragment, injected once weekly at 0.75 to 4.5 mg, made by Eli Lilly and approved in 2014. Victoza is liraglutide, a lipid-modified GLP-1 peptide injected once daily at 0.6 to 1.8 mg, made by Novo Nordisk and approved in 2010. Both carry FDA cardiovascular risk-reduction indications built on separate outcomes trials (REWIND for Trulicity, LEADER for Victoza), and both carry the class thyroid C-cell tumor boxed warning.

Question 2

Which causes more weight loss, Trulicity or Victoza?

Accepted Answer

Neither is labeled for weight management, and the average losses are similar. Victoza 1.8 mg daily produced about 2.8 kg of weight loss (roughly 3.2% of baseline body weight) in the LEADER trial's diabetes population. Trulicity 1.5 mg weekly runs 2 to 3 kg across the AWARD program, with the higher 3 mg and 4.5 mg doses extending that to roughly 3 to 4 kg in AWARD-11. The AWARD-6 head-to-head found comparable, modest weight loss on both molecules. Patients whose main goal is weight reduction should be looking at Wegovy (high-dose semaglutide), Zepbound, or Saxenda (liraglutide 3 mg) instead, each of which carries an obesity label.

Question 3

Can I switch between Trulicity and Victoza?

Accepted Answer

Yes, switching either direction is medically routine under prescriber supervision, though the daily-to-weekly rhythm change takes some adjustment. Liraglutide clears quickly (half-life about 13 hours) and dulaglutide within roughly a week, so no extended washout is needed. The typical plan is to stop the current drug and start the other at its starter dose the next scheduled day — Victoza at 0.6 mg daily for one week, or Trulicity at 0.75 mg weekly for four weeks — before moving to maintenance. Insurance approvals for the new agent often want documentation of why the switch is appropriate, and gastrointestinal side effects can return during re-titration.

Question 4

Which has fewer side effects, Trulicity or Victoza?

Accepted Answer

Trulicity looks milder on paper, partly because its dose profile is less steep. Trulicity reports nausea around 12 to 21%, diarrhea 8 to 13%, and vomiting 6 to 12% in the AWARD trials. Victoza runs higher across the board at its 1.8 mg daily dose, with nausea near 28%, diarrhea 17%, and vomiting 11% in LEADER. Some of the gap reflects Victoza's daily peak-and-trough exposure versus Trulicity's flatter weekly curve. Both carry the class thyroid C-cell tumor boxed warning, pancreatitis caution, and gallbladder-event risk. Slow titration blunts symptoms on either. Individual tolerance varies more than the averages suggest.

Question 5

Is Trulicity or Victoza cheaper?

Accepted Answer

Victoza has a real 2026 cost advantage because generic liraglutide launched in the United States in 2024 at Victoza-equivalent doses and typically sits well below brand Victoza on cash price. Trulicity remains brand-only with no generic competitor. Most commercial plans cover either for type 2 diabetes with prior authorization, with preferred-tier copays landing between $25 and $150 per month. Medicare Part D covers both for diabetes indications, and Eli Lilly and Novo Nordisk each run savings cards for commercial patients who qualify. Cash-pay and high-deductible patients often find generic liraglutide the meaningfully cheaper path.

Question 6

Are Trulicity and Victoza the same drug?

Accepted Answer

No. Different molecules, different manufacturers, different dosing rhythms. Trulicity is dulaglutide — a lab-engineered fusion protein linking a GLP-1 analogue to a modified IgG4 antibody fragment, which is what stretches its half-life enough for weekly injection. Victoza is liraglutide — a shorter peptide engineered with a fatty acid side chain that binds albumin and extends the half-life to roughly 13 hours, which is why dosing is daily. Eli Lilly makes Trulicity; Novo Nordisk makes Victoza. Both activate the GLP-1 receptor, but each carries its own prescribing information, label, and insurance pathway — they are not substitutable at the pharmacy.

Question 7

Which has better cardiovascular outcome data, Trulicity or Victoza?

Accepted Answer

Both have FDA cardiovascular risk-reduction indications, but the trials underneath them asked different questions. LEADER enrolled 9,340 patients with type 2 diabetes — roughly 81% with established cardiovascular disease and about 19% who were high-risk without a prior event — and showed Victoza 1.8 mg daily reduced major adverse cardiovascular events by 13% over a median 3.8 years. The FDA narrowed Victoza's resulting CV label to adults with established CVD. REWIND was broader: 9,901 patients including many with risk factors but no prior heart attack or stroke, and Trulicity 1.5 mg weekly produced a 12% MACE reduction over 5.4 years. That primary-prevention inclusion is why Trulicity's CV indication covers a wider diabetes population than Victoza's. Neither trial outperforms the other; they defined different at-risk groups.

Question 8

Is there a generic version of Victoza or Trulicity?

Accepted Answer

Only Victoza has a generic in 2026. Generic liraglutide at Victoza doses (up to 1.8 mg daily) launched in the United States in 2024 after the first liraglutide patent expirations, making it one of the earliest meaningful generic entries in the entire GLP-1 class. Automatic substitution is permitted under state pharmacy rules in most states, and generic liraglutide typically prices well below branded Victoza. Trulicity is still patent-protected and brand-only; no authorized generic or biosimilar dulaglutide has reached the U.S. market as of April 2026. For patients paying cash or facing high deductibles, the generic-liraglutide option tilts the cost calculation decisively toward the Victoza side.

Feature	Trulicity(dulaglutide)	Victoza(liraglutide)
Active Ingredient	dulaglutide	liraglutide
Drug Class	GLP-1 receptor agonist	GLP-1 receptor agonist
Manufacturer	Eli Lilly	Novo Nordisk
FDA Approved	2014-09-18	2010-01-25
Approved Indications	Type 2 diabetes mellitus (adjunct to diet and exercise) Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors	Type 2 diabetes mellitus (adjunct to diet and exercise) Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease Type 2 diabetes in patients aged 10+ years
Route	subcutaneous injection	subcutaneous injection
Frequency	Once weekly	Once daily
Starting Dose	0.75 mg weekly	0.6 mg daily
Maintenance Dose	1.5 mg weekly	1.2 mg or 1.8 mg daily
Max Dose	4.5 mg weekly	1.8 mg daily
Weight Loss (%)	3.1%	3.2%
A1C Reduction	1.5%	1.1%
Key Trial	REWIND (260 weeks)	LEADER (188 weeks)
List Price	$950-$1,100/month	$950-$1,100/month
With Insurance	$25-$150/month (varies by plan)	$25-$150/month (varies by plan)
Savings Card	$25/month (Lilly savings card, commercially insured)	$25/month (Novo Nordisk savings card, commercially insured)

Side Effect	Trulicity	Victoza
Nausea	12-21%	28%
Diarrhea	8-13%	17%
Vomiting	6-12%	11%
Abdominal pain	6-9%	Not reported
Decreased appetite	4-9%	9%
Dyspepsia	4-6%	7%
Fatigue	4-6%	Not reported
Pancreatitis (rare)	<0.5%	<1%
Headache	Not reported	9%
Constipation	Not reported	6%

Trulicity vs Victoza

Summary

FDA-Approved Indications and CV Labels

Efficacy and Clinical Use

Side Effects, Cost, and Practical Considerations

Trulicity vs Victoza: Full Comparison

Side Effects: Trulicity vs Victoza

Related Comparisons

Frequently Asked Questions

Sources & References

FDA & Regulatory

Clinical Trial Records

Peer-Reviewed Literature

Manufacturer Information

Reference Entries

Additional References